Logo image of XLO

XILIO THERAPEUTICS INC (XLO) Stock Fundamental Analysis

NASDAQ:XLO - US98422T1007 - Common Stock

0.7001 USD
+0.01 (+1.39%)
Last: 8/29/2025, 8:00:19 PM
0.69 USD
-0.01 (-1.44%)
After Hours: 8/29/2025, 8:00:19 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to XLO. XLO was compared to 547 industry peers in the Biotechnology industry. While XLO seems to be doing ok healthwise, there are quite some concerns on its profitability. XLO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year XLO has reported negative net income.
XLO had a negative operating cash flow in the past year.
In the past 5 years XLO always reported negative net income.
In the past 5 years XLO always reported negative operating cash flow.
XLO Yearly Net Income VS EBIT VS OCF VS FCFXLO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

XLO has a Return On Assets (-42.02%) which is in line with its industry peers.
With a Return On Equity value of -795.33%, XLO is not doing good in the industry: 80.26% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -42.02%
ROE -795.33%
ROIC N/A
ROA(3y)-90.24%
ROA(5y)-91.52%
ROE(3y)-207.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XLO Yearly ROA, ROE, ROICXLO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800 1K

1.3 Margins

XLO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XLO Yearly Profit, Operating, Gross MarginsXLO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

6

2. Health

2.1 Basic Checks

XLO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XLO has been increased compared to 1 year ago.
XLO has more shares outstanding than it did 5 years ago.
There is no outstanding debt for XLO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
XLO Yearly Shares OutstandingXLO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
XLO Yearly Total Debt VS Total AssetsXLO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -4.80, we must say that XLO is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.80, XLO is in line with its industry, outperforming 40.77% of the companies in the same industry.
XLO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.8
ROIC/WACCN/A
WACC9.57%
XLO Yearly LT Debt VS Equity VS FCFXLO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 2.32 indicates that XLO has no problem at all paying its short term obligations.
XLO has a worse Current ratio (2.32) than 70.57% of its industry peers.
XLO has a Quick Ratio of 2.32. This indicates that XLO is financially healthy and has no problem in meeting its short term obligations.
XLO has a Quick ratio of 2.32. This is in the lower half of the industry: XLO underperforms 68.37% of its industry peers.
Industry RankSector Rank
Current Ratio 2.32
Quick Ratio 2.32
XLO Yearly Current Assets VS Current LiabilitesXLO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

3

3. Growth

3.1 Past

XLO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.98%, which is quite impressive.
XLO shows a strong growth in Revenue. In the last year, the Revenue has grown by 536.44%.
EPS 1Y (TTM)63.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)536.44%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%242.98%

3.2 Future

The Earnings Per Share is expected to grow by 18.00% on average over the next years. This is quite good.
Based on estimates for the next years, XLO will show a small growth in Revenue. The Revenue will grow by 5.36% on average per year.
EPS Next Y87.77%
EPS Next 2Y30.84%
EPS Next 3Y16.71%
EPS Next 5Y18%
Revenue Next Year782.62%
Revenue Next 2Y84.47%
Revenue Next 3Y27.92%
Revenue Next 5Y5.36%

3.3 Evolution

XLO Yearly Revenue VS EstimatesXLO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
XLO Yearly EPS VS EstimatesXLO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XLO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XLO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XLO Price Earnings VS Forward Price EarningsXLO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XLO Per share dataXLO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as XLO's earnings are expected to grow with 16.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.84%
EPS Next 3Y16.71%

0

5. Dividend

5.1 Amount

XLO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

XILIO THERAPEUTICS INC

NASDAQ:XLO (8/29/2025, 8:00:19 PM)

After market: 0.69 -0.01 (-1.44%)

0.7001

+0.01 (+1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners22.99%
Inst Owner Change5.32%
Ins Owners0.75%
Ins Owner Change0.78%
Market Cap36.29M
Analysts80
Price Target2.04 (191.39%)
Short Float %13.63%
Short Ratio9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-192.81%
Min EPS beat(2)-287.6%
Max EPS beat(2)-98.02%
EPS beat(4)2
Avg EPS beat(4)-91.33%
Min EPS beat(4)-287.6%
Max EPS beat(4)11.7%
EPS beat(8)4
Avg EPS beat(8)-100.06%
EPS beat(12)7
Avg EPS beat(12)-63.15%
EPS beat(16)9
Avg EPS beat(16)-122.29%
Revenue beat(2)0
Avg Revenue beat(2)-18.29%
Min Revenue beat(2)-34.07%
Max Revenue beat(2)-2.51%
Revenue beat(4)0
Avg Revenue beat(4)-29.24%
Min Revenue beat(4)-48.27%
Max Revenue beat(4)-2.51%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-50%
PT rev (3m)-50%
EPS NQ rev (1m)90.63%
EPS NQ rev (3m)93.66%
EPS NY rev (1m)74.59%
EPS NY rev (3m)74.59%
Revenue NQ rev (1m)144.33%
Revenue NQ rev (3m)211.73%
Revenue NY rev (1m)170.48%
Revenue NY rev (3m)170.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.42
P/FCF N/A
P/OCF N/A
P/B 5.13
P/tB 5.13
EV/EBITDA N/A
EPS(TTM)-0.76
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0.29
BVpS0.14
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.02%
ROE -795.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-90.24%
ROA(5y)-91.52%
ROE(3y)-207.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.81%
Cap/Sales 2.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.32
Quick Ratio 2.32
Altman-Z -4.8
F-Score6
WACC9.57%
ROIC/WACCN/A
Cap/Depr(3y)42.95%
Cap/Depr(5y)81.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y87.77%
EPS Next 2Y30.84%
EPS Next 3Y16.71%
EPS Next 5Y18%
Revenue 1Y (TTM)536.44%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%242.98%
Revenue Next Year782.62%
Revenue Next 2Y84.47%
Revenue Next 3Y27.92%
Revenue Next 5Y5.36%
EBIT growth 1Y15.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year94.76%
EBIT Next 3Y9.46%
EBIT Next 5Y12.01%
FCF growth 1Y83.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y83.33%
OCF growth 3YN/A
OCF growth 5YN/A